489 related articles for article (PubMed ID: 12712480)
21. Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma.
Blesa D; Mollejo M; Ruano Y; de Lope AR; Fiaño C; Ribalta T; García JF; Campos-Martín Y; Hernández-Moneo JL; Cigudosa JC; Meléndez B
J Neuropathol Exp Neurol; 2009 Mar; 68(3):274-85. PubMed ID: 19225409
[TBL] [Abstract][Full Text] [Related]
22. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas.
Senetta R; Trevisan E; Rudà R; Maldi E; Molinaro L; Lefranc F; Chiusa L; Lanotte M; Soffietti R; Cassoni P
J Neuropathol Exp Neurol; 2009 Apr; 68(4):425-31. PubMed ID: 19287309
[TBL] [Abstract][Full Text] [Related]
23. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
24. Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications.
Birner P; Preusser M; Gelpi E; Berger J; Gatterbauer B; Ambros IM; Ambros PF; Acker T; Plate KH; Harris AL; Hainfellner JA
Clin Cancer Res; 2004 Oct; 10(19):6567-71. PubMed ID: 15475445
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
[TBL] [Abstract][Full Text] [Related]
26. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
27. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.
Jenkinson MD; Smith TS; Joyce KA; Fildes D; Broome J; du Plessis DG; Haylock B; Husband DJ; Warnke PC; Walker C
Neuroradiology; 2006 Oct; 48(10):703-13. PubMed ID: 16937145
[TBL] [Abstract][Full Text] [Related]
28. Survival analysis of presumptive prognostic markers among oligodendrogliomas.
McLendon RE; Herndon JE; West B; Reardon D; Wiltshire R; Rasheed BK; Quinn J; Friedman HS; Friedman AH; Bigner DD
Cancer; 2005 Oct; 104(8):1693-9. PubMed ID: 16116609
[TBL] [Abstract][Full Text] [Related]
29. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.
Ino Y; Betensky RA; Zlatescu MC; Sasaki H; Macdonald DR; Stemmer-Rachamimov AO; Ramsay DA; Cairncross JG; Louis DN
Clin Cancer Res; 2001 Apr; 7(4):839-45. PubMed ID: 11309331
[TBL] [Abstract][Full Text] [Related]
30. Chromosome 1p loss evaluation in anaplastic oligodendrogliomas.
Idbaih A; Kouwenhoven M; Jeuken J; Carpentier C; Gorlia T; Kros JM; French P; Teepen JL; Delattre O; Delattre JY; van den Bent M; Hoang-Xuan K
Neuropathology; 2008 Aug; 28(4):440-3. PubMed ID: 18312547
[TBL] [Abstract][Full Text] [Related]
31. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
Kros JM; Gorlia T; Kouwenhoven MC; Zheng PP; Collins VP; Figarella-Branger D; Giangaspero F; Giannini C; Mokhtari K; Mørk SJ; Paetau A; Reifenberger G; van den Bent MJ
J Neuropathol Exp Neurol; 2007 Jun; 66(6):545-51. PubMed ID: 17549014
[TBL] [Abstract][Full Text] [Related]
32. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
Franco-Hernández C; Martínez-Glez V; de Campos JM; Isla A; Vaquero J; Gutiérrez M; Casartelli C; Rey JA
Cancer Genet Cytogenet; 2009 Apr; 190(2):93-6. PubMed ID: 19380026
[TBL] [Abstract][Full Text] [Related]
33. Glioneuronal tumor with neuropil-like islands (GTNI): a report of 8 cases with chromosome 1p/19q deletion analysis.
Barbashina V; Salazar P; Ladanyi M; Rosenblum MK; Edgar MA
Am J Surg Pathol; 2007 Aug; 31(8):1196-202. PubMed ID: 17667543
[TBL] [Abstract][Full Text] [Related]
34. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
[TBL] [Abstract][Full Text] [Related]
35. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
Kanner AA; Staugaitis SM; Castilla EA; Chernova O; Prayson RA; Vogelbaum MA; Stevens G; Peereboom D; Suh J; Lee SY; Tubbs RR; Barnett GH
J Neurosurg; 2006 Apr; 104(4):542-50. PubMed ID: 16619658
[TBL] [Abstract][Full Text] [Related]
36. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
37. Cyclooxygenase-2 in oligodendroglial neoplasms.
Castilla EA; Prayson RA; Kanner AA; Rybicki LA; Tubbs RR; Vogelbaum MA; Barnett GH
Cancer; 2003 Oct; 98(7):1465-72. PubMed ID: 14508834
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiles associated with treatment response in oligodendrogliomas.
French PJ; Swagemakers SM; Nagel JH; Kouwenhoven MC; Brouwer E; van der Spek P; Luider TM; Kros JM; van den Bent MJ; Sillevis Smitt PA
Cancer Res; 2005 Dec; 65(24):11335-44. PubMed ID: 16357140
[TBL] [Abstract][Full Text] [Related]
39. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
Reifenberger J; Reifenberger G; Liu L; James CD; Wechsler W; Collins VP
Am J Pathol; 1994 Nov; 145(5):1175-90. PubMed ID: 7977648
[TBL] [Abstract][Full Text] [Related]
40. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
